TJM Labs Revenue, Valuation & Funding (2026)

TJM Labs reported approximately $25 million in ARR as of mid-2026, up from $15 million at the end of December 2025 and $1 million in February 2025, when the company began selling beyond its first customer. That trajectory represents growth of roughly 2,400 percent from the February 2025 starting point. The last six months alone added $10 million in ARR.

TJM Labs had approximately 450 pharmacy logos under contract as of mid-2026, up from 1 customer in late 2024 and roughly 30 customers acquired through pure relationships and referrals by early 2025. The company added 449 net new customers from that base to reach 450.

The average contract value is $45,000 per bot per year, structured as a digital worker annual subscription. The average pharmacy uses approximately 2.5 bots, implying an average revenue per pharmacy of roughly $112,500 per year. The largest single customer, the company's first, was paying more than $1 million per year as of 2025. Enterprise contracts in healthcare generally carry a minimum of $250,000 per year, according to Adly.

Adly confirmed the pricing structure: "Our average ACV is about forty five K a year. And if you notice, that is slightly less than the salary of a pharmacy technician, and that's how we price it. We, this is digital workers. That's what you should hold the company accountable for. And you can hire a digital worker for forty five K a year, or you can hire three human workers and that will cost you 150K a year." The first 30 customers were acquired through relationships and referrals. LinkedIn outbound became the primary growth channel thereafter.

TJM Labs sells annual subscriptions priced per digital worker bot at $45,000 per year. The model is explicitly positioned as labor replacement rather than software licensing: one bot replaces two to three pharmacy technicians, who would cost approximately $150,000 per year combined before benefits and payroll overhead. The company does not use per-seat or per-task pricing.

The company reported 40 percent EBITDA margins and 40 percent gross margins as of mid-2026. Adly confirmed profitability directly: "We had forty percent EBITDA." The company described itself as still profitable going into the Series B and intends to remain profitable while deploying the new capital toward M and A and headcount growth.

The two acquisitions completed, Encore RX (Ancore) in 2025 and PharmaSol (Reformers) in 2026, contributed less than 5 percent of total ARR. Their combined revenue at acquisition was under $2 million to $3 million. The acquisitions were described as primarily team-driven rather than revenue-driven.

The addressable market framing used internally: 16,000 total U.S. pharmacies, an average of 2.5 bots per pharmacy at $45,000 per bot, implies a total addressable ARR of approximately $1.8 billion at full penetration. The company's bots were processing approximately 500,000 prescriptions per day as of roughly three months before the July 2026 interview, measured via bot metadata rather than retained prescription data, consistent with a zero data retention policy.

Retail pharmacy gross margins average approximately 2 percent before deploying TJM Labs bots and rise to approximately 8 percent after implementation, according to Adly. The ARR growth in the six months ending mid-2026 was $10 million. The target ARR milestone discussed with Elephant investors was $100 million. Profitability, churn, LTV, CAC, and net revenue retention were not discussed in the interview.

Headcount and team composition were not discussed in the interview. The company noted it made two acquisitions primarily for the teams they brought, and that the Series B capital would be used in part to ramp hiring, but no specific employee count was provided.